AstraZeneca plc (AZN) Given a GBX 4,550 Price Target by UBS AG Analysts
AstraZeneca plc (LON:AZN) has been assigned a GBX 4,550 ($60.46) target price by equities researchers at UBS AG in a research report issued on Monday, www.boersen-zeitung.de reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS AG’s target price would suggest a potential downside of 11.86% from the stock’s current price.
AZN has been the subject of several other reports. Liberum Capital reissued a “buy” rating and issued a GBX 4,800 ($63.78) price target on shares of AstraZeneca plc in a research note on Tuesday, September 5th. HSBC Holdings plc boosted their price target on shares of AstraZeneca plc from GBX 4,100 ($54.48) to GBX 4,150 ($55.14) and gave the stock a “reduce” rating in a research note on Monday, October 9th. Jefferies Group LLC boosted their price target on shares of AstraZeneca plc from GBX 4,350 ($57.80) to GBX 4,800 ($63.78) and gave the stock a “hold” rating in a research note on Monday, September 11th. Deutsche Bank AG reissued a “buy” rating and issued a GBX 5,700 ($75.74) price target on shares of AstraZeneca plc in a research note on Friday, July 28th. Finally, Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research note on Tuesday, August 29th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of GBX 5,172.64 ($68.73).
Shares of AstraZeneca plc (LON AZN) traded up 0.04% on Monday, reaching GBX 5164.00. The company had a trading volume of 860,751 shares. The company’s 50-day moving average is GBX 4,923.51 and its 200-day moving average is GBX 4,914.37. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The company’s market capitalization is GBX 65.38 billion.
ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/23/astrazeneca-plc-azn-given-a-gbx-4550-price-target-by-ubs-ag-analysts-3.html.
In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.